Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01178 (
oxytocin
)
15,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The regulation of neuropeptide level at the site of release is essential for proper neurophysiological functions. We focused on a prominent neuropeptide,
oxytocin
(
OXT
) in the zebrafish as an in vivo model to visualize and quantify
OXT
content at the resolution of a single synapse. We found that
OXT
-loaded synapses were enriched with polymerized actin. Perturbation of actin filaments by either cytochalasin-D or conditional Cofilin expression resulted in decreased synaptic
OXT
levels. Genetic loss of
robo2
or
slit3
displayed decreased synaptic
OXT
content and
robo2
mutants displayed reduced mobility of the actin probe Lifeact-EGFP in
OXT
synapses. Using a novel transgenic reporter allowing real-time monitoring of
OXT
-loaded vesicles, we show that
robo2
mutants display slower rate of vesicles accumulation.
OXT
-specific expression of dominant-negative Cdc42, which is a key regulator of actin dynamics and a downstream effector of Robo2, led to a dose-dependent increase in
OXT
content in WT, and a dampened effect in
robo2
mutants. Our results link Slit3-Robo2-Cdc42, which controls local actin dynamics, with the maintenance of synaptic neuropeptide levels.
...
PMID:Robo2 regulates synaptic oxytocin content by affecting actin dynamics. 3301 83